F S&P 500
5,212.00 -1.75 (-0.03%) F Dow Jones
39,012.00 -15.00 (-0.04%) F Nasdaq
18,192.00 -7.50 (-0.04%) E-mini Russell 2000 Index Futur
2,072.10 -4.60 (-0.22%) Petróleo
78.05 -0.33 (-0.42%) Oro
2,326.90 +2.70 (+0.12%)
Morphic Holding, Inc. (MORF)
Fuera de horario:
Morphic Holding, Inc.
35 Gatehouse Drive, A2
Waltham, MA 02451
United States
781 996 0955
https://www.morphictx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 124
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Praveen P. Tipirneni M.D. | CEO, MD & Director | 1.04M | N/D | 1968 |
| Dr. Bruce N. Rogers Ph.D. | President | 857.34k | N/D | 1969 |
| Dr. Timothy A. Springer Ph.D. | Founder, Independent Director & Member of Scientific Advisory Board | 40k | N/D | 1948 |
| Dr. Marc Schegerin M.B.A., M.D. | CFO & COO | 769.25k | N/D | 1976 |
| Mr. Robert E. Farrell Jr., CPA | Senior VP of Finance & Chief Accounting Officer | 645.5k | N/D | 1965 |
| Dr. Blaise Lippa Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
| Mr. William D. DeVaul Esq. | General Counsel & Secretary | 601.44k | 4.32M | 1971 |
| Mr. Aaron Pelta | Senior Vice President of Business & Corporate Development | N/D | N/D | N/D |
| Ms. Joanne Gibbons | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Dr. Simon Cooper MBBS | Chief Medical Officer | N/D | N/D | 1970 |
Descripción
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Morphic Holding, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 4; Junta: 7; Derechos del accionista: 8; Compensación: 9.
